Page 124 - Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis
P. 124
Chapter 5
41. Dalm SU, Bakker IL, de Blois E, et al (2017) 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med 58:293-299.
42. Mansour N, Paquette M, Ait-Mohand S, Dumulon-Perreault V, Guerin B (2018) Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [(64)Cu]-DOTHA2-PEG-RM26. Nucl Med Biol 56:31-38.
43. Mansi R, Wang X, Forrer F, et al (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97-107.
44. Lutje S, Rijpkema M, Helfrich W, Oyen WJ, Boerman OC (2014) Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation. Mol Imaging Biol 16:747-755.
45. Kaloudi A, Nock BA, Lymperis E, et al (2016) Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation. EJNMMI Res 6:15.
46. Nieciecki M, Dobruch-Sobczak K, Wareluk P, et al (2016) The role of ultrasound and lymphoscintigraphy in the assessment of axillary lymph nodes in patients with breast cancer. J Ultrason 16:5-15.
122
